Axamon, 5 mg/ml 1 ml 10 pcs

Axamon® is a reversible cholinesterase inhibitor and directly stimulates impulse conduction at the neuromuscular synapse and in the central nervous system (CNS) due to blockade of membrane potassium channels. It enhances the effect on smooth muscles not only of acetylcholine but also of adrenaline, serotonin, histamine and oxytocin.

Axamon® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;

– improves conduction in the peripheral nervous system, impaired due to trauma, inflammation, exposure to local anesthetic, some antibiotics, potassium chloride, etc.

– increases the contractility of smooth-muscular organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except for potassium chloride;

– improves memory, inhibits the progradient development of dementia.

It does not have teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects. It does not influence the endocrine system.

Indications

Stroke Consequences, Polyneuropathy, Attention and Memory Disorders, Alzheimer’s Disease

• diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia and myasthenic syndrome of various etiology;
• CNS diseases: bulbar paralysis and paresis;
• recovery period of organic CNS lesions accompanied by motor disorders;
• intestinal atony.

.

Active ingredient

Ipidacrine

How to take, the dosage

Subcutaneously or intramuscularly. Doses and duration of treatment are determined individually depending on the severity of the disease.
Peripheral nervous system diseases:
– mono- and polyneuropathies of different genesis, polyradiculopathies: subcutaneously or intramuscularly 5-15 mg 1-2 times a day, 10-15 days course (in severe cases – up to 30 days); after that treatment is continued by tablet form of the drug;
– myasthenia gravis and myasthenic syndrome: subcutaneously or intramuscularly 15-30 mg 1-3 times a day with subsequent change to tablet form. Total course of treatment is 1-2 months. If necessary, treatment may be repeated several times with a break between courses of 1-2 months.

CNS diseases

– bulbar paralysis and paresis: subcutaneously or intramuscularly 5-15 mg 1-2 times a day, 10-15 days course; afterwards, if possible switch to tablet form;
– rehabilitation period of organic CNS lesions accompanied by movement disorders: intramuscularly 10-15 mg 1-2 times a day, course up to 15 days; then, if possible, switch to the tablet form.

The treatment and prevention of bowel atony: the initial dose is 10-15 mg 1-2 times a day for 1-2 weeks.

Interaction

Aksamon® increases the sedative effect in combination with drugs that depress the central nervous system.

Special Instructions

During treatment, it is necessary to refrain from driving a car, other vehicles and mechanisms, as well as from potentially dangerous activities that require high concentration and quick psychomotor reactions.

Contraindications

• Hypersensitivity to any of the ingredients,
• Epilepsy,
• extrapyramidal disorders with hyperkinesias,
• stenocardia,
• expressive bradycardia,
• bronchial asthma,
• mechanical bowel or urinary tract obstruction,
• vestibular disorders,
• acute gastric or duodenal ulcer,
• children under 18 years of age (no systematic data on use are available).

With caution in: gastric and duodenal ulcer, thyrotoxicosis, cardiovascular disease, obstructive diseases of the respiratory system in the anamnesis or acute respiratory diseases.
If you have one of the above diseases, be sure to consult with your doctor before taking the drug.

Side effects

The frequency of adverse reactions that may occur during the use of the drug is given in the following classification: very frequent (>1/10 appointments), frequent (1/10-1/100 appointments), infrequent (1/100-1/1000 appointments), rare (1/1000-1/10000 appointments), very rare (Psychiatric disorders: infrequent – somnolence.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, constricted pupils, nystagmus, increased gastrointestinal peristalsis, spontaneous defecation and urination, vomiting, jaundice, bradycardia, intracardiac conduction disorder, arrhythmias, decreased blood pressure, anxiety, restlessness, agitation, fear, ataxia, seizures, coma, speech disorders, sleepiness and general weakness.

Similarities

Neuromidine, Ipigrix